Compositions and Methods for Editing Cytoplasmic DNA
OwnerAdam Joseph Schieferecke, David V. Schaffer +2inventors
InventorsAdam Joseph Schieferecke, David V. Schaffer, John E. Dueber, Juan Eduardo Hurtado Koolik
Life of this patent
Estimating the term…
Abstract
The present disclosure provides systems and methods for modifying a target viral nucleic acid in the cytoplasm of a eukaryotic cell.
Claims22
A method of modifying a target viral nucleic acid in the cytoplasm of a eukaryotic cell, the method comprising contacting the target viral nucleic acid with:
- a) a fusion polypeptide comprising:
- i) a CRISPR-Cas effector polypeptide;
- and ii) two or more heterologous polypeptides, wherein one of the two or more heterologous polypeptides is an error-prone DNA polymerase and wherein one of the two or more heterologous polypeptides comprises a nuclear export signal (NES) polypeptide;
- and
- b) one or more guide nucleic acids, wherein one or more guide nucleic acids comprise:
- i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target viral nucleic acid;
- and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide,
- wherein said contacting provides for modification of the target viral nucleic acid.
(canceled)
-13. (canceled)
(canceled)
A method of modifying a target viral nucleic acid in the cytoplasm of a eukaryotic cell, the method comprising:
- A) introducing into the eukaryotic cell gene editing components, wherein the gene editing components comprise:
- a) a fusion polypeptide comprising:
- i) a CRISPR-Cas effector polypeptide;
- and ii) two or more heterologous polypeptides, wherein one of the two or more heterologous polypeptides is an error-prone DNA polymerase and wherein one of the two or more heterologous polypeptides comprises a nuclear export signal (NES) polypeptide;
- and
- b) one or more guide nucleic acids, wherein one or more guide nucleic acids comprise:
- i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target viral nucleic acid;
- and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide, thereby generating a modified eukaryotic cell;
- and
- B) infecting the modified eukaryotic cell with a virus comprising the target viral nucleic acid, wherein the target viral nucleic acid is contacted with the gene editing components, and wherein said contacting provides for modification of the target viral nucleic acid.
A system for modifying a target viral nucleic acid in the cytoplasm of a eukaryotic cell, the system comprising:
- a1) a fusion polypeptide comprising:
- i) a CRISPR-Cas effector polypeptide that exhibits nickase activity;
- and ii) two or more heterologous polypeptides, wherein one of the two or more heterologous polypeptides is an error-prone DNA polymerase that lacks all or a portion of a 3′-to-5′ exonuclease domain and/or lacks all or a portion of a 5′-to-3′ exonuclease domain, wherein one of the two or more heterologous polypeptides comprises a nuclear export signal (NES) polypeptide, and wherein the two or more heterologous polypeptides does not include a nuclear localization signal (NLS) polypeptide;
- and
- b1) one or more guide nucleic acids, wherein one or more guide nucleic acids comprise:
- i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target viral nucleic acid, wherein the nucleotide sequence that binds to the target sequence has a length of from 15 nucleotides to 18 nucleotides;
- and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide;
- or
- a2) a nucleic acid comprising a nucleotide sequence encoding a fusion polypeptide comprising:
- i) a CRISPR-Cas effector polypeptide that exhibits nickase activity;
- and ii) two or more heterologous polypeptides, wherein one of the two or more heterologous polypeptides is an error-prone DNA polymerase that lacks all or a portion of a 3′-to-5′ exonuclease domain and/or lacks all or a portion of a 5′-to-3′ exonuclease domain, wherein one of the two or more heterologous polypeptides comprises an NES polypeptide, and wherein the two or more heterologous polypeptides does not include an NLS polypeptide;
- and
- b2) one or more guide nucleic acids, wherein one or more guide nucleic acids comprise:
- i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target viral nucleic acid, wherein the nucleotide sequence that binds to the target sequence has a length of from 15 nucleotides to 18 nucleotides;
- and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide;
- or
- a3) a nucleic acid comprising:
- 1) a first nucleotide sequence encoding a fusion polypeptide comprising:
- i) a CRISPR-Cas effector polypeptide that exhibits nickase activity;
- and ii) two or more heterologous polypeptides, wherein one of the two or more heterologous polypeptides is an error-prone DNA polymerase that lacks all or a portion of a 3′-to-5′ exonuclease domain and/or lacks all or a portion of a 5′-to-3′ exonuclease domain, wherein one of the two or more heterologous polypeptides comprises an NES polypeptide, and wherein the two or more heterologous polypeptides does not include an NLS polypeptide;
- and
- 2) a second nucleotide sequence encoding one or more guide nucleic acids, wherein one or more guide nucleic acids comprise:
- i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target viral nucleic acid, wherein the nucleotide sequence that binds to the target sequence has a length of from 15 nucleotides to 18 nucleotides;
- and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide.
Dependencies are inferred from the claim text.